ReviewJournal of breast cancer2013
The korean hereditary breast cancer study: review and future perspectives.
Review in Journal of breast cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.BMC cancer · 2022Pooled it
- Exploring Traditional Breast Cancer Risk Genes Among Aboriginal and Torres Strait Islander Women.Life (Basel, Switzerland) · 2026Article
- Age and Late Recurrence in Young Patients With ER-Positive, ERBB2-Negative Breast Cancer.JAMA network open · 2024Article
- Pattern Anlysis of Risk-Reducing Strategies in Unaffected KoreanCurrent oncology (Toronto, Ont.) · 2024Article
- Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer.Cancer chemotherapy and pharmacology · 2024Article
- Increased risk of contralateral breast cancer for BRCA1/2 wild-type, high-risk Korean breast cancer patients: a retrospective cohort study.Breast cancer research : BCR · 2024Article
- Acceptability and Usability of the Family Gene Toolkit for Swiss and Korean Families HarboringCancers · 2023Article
- Differences in Willingness to UndergoJournal of personalized medicine · 2022Article
- Identification of the most common BRCA alterations through analysis of germline mutation databases: Is droplet digital PCR an additional strategy for the assessment of such alterations in breast and ovarian cancer families?International journal of oncology · 2022Article
- Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.Breast cancer (Tokyo, Japan) · 2021Review
- Disparities between Uptake of GermlineJournal of Korean medical science · 2021Article
- Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer.Journal of personalized medicine · 2021Review
- BRCA and Breast Cancer-Related High-Penetrance Genes.Advances in experimental medicine and biology · 2021Review
- Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of theJournal of breast cancer · 2020Article
- Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant.Cancer research and treatment · 2020Article
- Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence inJournal of breast cancer · 2019Article
- Analysis of clinical characteristics of breast cancer patients with the Japanese founder mutationOncotarget · 2019Article
- Influence of the Angelina Jolie Announcement and Insurance Reimbursement on Practice Patterns for Hereditary Breast Cancer.Journal of breast cancer · 2017Article
- Comparison of Clinical Outcomes ofCancer research and treatment · 2017Article
- Characteristics and Survival of Breast Cancer Patients with Multiple Synchronous or Metachronous Primary Cancers.Yonsei medical journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most studies related to BRCA mutations have been performed in Western populations, and only a few small studies have been conducted in Korean populations. In 2007, the Korean Hereditary Breast Cancer (KOHBRA) Study was established to obtain evidence for the accurate risk assessment and management of hereditary breast and ovarian cancer (HBOC) in Korea. Between May 2007 and May 2010, the first phase of the KOHBRA Study was performed to estimate the prevalence of BRCA1/2 mutations among patients and their families at risk for HBOC. Between June 2010 and May 2013, the second phase of the KOHBRA Study was performed to identify the clinical characteristics and prognostic indicators of BRCA-related breast cancer and environmental and genetic modifiers of BRCA mutations and to develop a Korean BRCA risk calculator and nationwide genetic counseling network for HBOC. Herein, we review the results of the KOHBRA Study and describe the future perspectives of the study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.